We would like to thank Professor Caussy for her editorial on our article. 1,2 She highlighted gradual improvements in the control of metabolic risk factors among patients with non-alcoholic fatty liver disease (NAFLD) in the past two decades, though there remains much room for improvement. In particular, metabolic drugs with